KeyCorp Lowers Stevanato Group (NYSE:STVN) Price Target to $32.00

Stevanato Group (NYSE:STVN) had its price objective lowered by stock analysts at KeyCorp from $37.00 to $32.00 in a research report issued to clients and investors on Thursday, Marketbeat.com reports. The firm presently has an “overweight” rating on the stock.

STVN has been the subject of a number of other reports. Morgan Stanley assumed coverage on shares of Stevanato Group in a research report on Monday, December 1st. They issued an “equal weight” rating and a $24.00 price objective for the company. Wall Street Zen downgraded Stevanato Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Jefferies Financial Group set a $17.50 price objective on Stevanato Group in a research note on Tuesday, February 10th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Stevanato Group in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Stevanato Group has a consensus rating of “Moderate Buy”.

Stevanato Group Stock Performance

NYSE:STVN opened at €15.46 on Thursday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.30 and a current ratio of 1.76. Stevanato Group has a 52-week low of €13.91 and a 52-week high of €28.00. The firm has a market cap of $4.68 billion, a price-to-earnings ratio of 26.66, a PEG ratio of 1.46 and a beta of 0.57. The business’s fifty day moving average is €17.58 and its 200 day moving average is €21.66.

Institutional Investors Weigh In On Stevanato Group

Hedge funds have recently made changes to their positions in the business. Ranger Investment Management L.P. grew its holdings in shares of Stevanato Group by 125.6% during the 2nd quarter. Ranger Investment Management L.P. now owns 1,321,030 shares of the company’s stock valued at $32,273,000 after purchasing an additional 735,417 shares during the last quarter. Loomis Sayles & Co. L P purchased a new position in shares of Stevanato Group in the second quarter worth about $13,729,000. Champlain Investment Partners LLC lifted its stake in shares of Stevanato Group by 68.7% in the 2nd quarter. Champlain Investment Partners LLC now owns 1,300,799 shares of the company’s stock valued at $31,779,000 after acquiring an additional 529,950 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new stake in Stevanato Group during the 4th quarter valued at about $9,269,000. Finally, Artisan Partners Limited Partnership grew its position in Stevanato Group by 20.0% during the 2nd quarter. Artisan Partners Limited Partnership now owns 2,733,782 shares of the company’s stock worth $66,786,000 after acquiring an additional 455,323 shares during the last quarter.

Stevanato Group News Roundup

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Q4 beats and revenue momentum — Stevanato reported Q4 results that beat expectations (reported EPS ~$0.2114 vs. ~$0.20 consensus) and highlighted strong revenue growth, reinforcing demand for its pharmaceutical packaging and high‑value solutions. STVN Q4 Highlights
• Positive Sentiment: 2026 guidance and HVS mix — Management outlined a 2026 revenue target up to €1.308B and expects high‑value solutions (HVS) to reach ~48% of sales, supporting margin expansion potential as capex is mainly HVS‑directed. 2026 Revenue Target Article
• Positive Sentiment: Analyst buy support — At least one note (Seeking Alpha piece) reiterates a Buy thesis citing Q4/FY25 strength and long‑term demand drivers, framing current weakness as cyclical in the Engineering segment. Stevanato: Strong Q4 Results Reinforce Long-Term Growth Story
• Neutral Sentiment: Earnings call detail — Full Q4/FY25 earnings call transcripts and summaries are available for deeper read; they provide management color on capex allocation (heavy toward HVS) and the cyclical pressure in Engineering. Useful for modeling near‑term margin recovery timing. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Transcripts published — Full call transcripts (Seeking Alpha / InsiderMonkey) confirm the beat and provide verbatim management commentary for investors building scenarios. Earnings Call Transcript
• Negative Sentiment: Multiple analyst price‑target cuts — Morgan Stanley cut its PT to $19 and moved to Equal Weight; Citigroup lowered its PT to $26 (maintained Buy); KeyCorp trimmed its PT to $32 (keeps Overweight). Those revisions reduce near‑term upside expectations and likely contributed to selling pressure. Analyst PT Changes (Benzinga) KeyBanc / StreetInsider

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.